Clinical Trial Update: To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema [Phase 3]

View source ↗

Summary

Phase 3 trial comparing brolucizumab to aflibercept in Chinese patients with diabetic macular edema has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• BEOVU (BROLUCIZUMAB)
• EYLEA (Aflibercept)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diabetic Macular Edema | Phase 3 | Status: COMPLETED | Results posted: 2024-09-19